Sun Pharma stock concerns may be overstated as domestic growth holds
Sun Pharma continues to outpace domestic market growth with strong chronic portfolio gains and resilient earnings, as analysts see concerns over US coverage and specialty bets as overstated
Sun Pharma continues to outpace domestic market growth with strong chronic portfolio gains and resilient earnings, as analysts see concerns over US coverage and specialty bets as overstated
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
